Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigenJC Aguilar, Gerardo Guillén, Yadira Lobaina et al.|Immunology and Cell Biology|2004Cited by 87
Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical TrialSheikh Mohammad Fazle Akbar, Yoichi Hiasa, Mamun Al Mahtab et al.|Pathogens|2021Cited by 24
The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical TrialSheikh Mohammad Fazle Akbar, Yoichi Hiasa, Mamun Al Mahtab et al.|Vaccines|2021Cited by 21
Virus-Like Particles as vaccine antigens and adjuvants: application to chronic disease, cancer immunotherapy and infectious disease preventive strategiesGerardo Guillén, Luís Herrera, Julio Aguilar et al.|Procedia in Vaccinology|2010Cited by 21
HBV Genotypic Variability in CubaCarmen L. Loureiro, Flor H. Pujol, Julio Aguilar et al.|PLoS ONE|2015Cited by 17